CheckMate 238 — Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma

Phase 3 · 2017 · Melanoma

Design

Randomized adjuvant nivolumab vs adjuvant ipilimumab for up to 1 year after complete resection.

Population

Completely resected stage IIIB/C or IV melanoma at high risk of recurrence.

Primary Endpoint

recurrence-free survival (RFS)

Key Result

4-yr RFS 51.7% vs 41.2% (HR 0.71) with markedly less grade 3-4 toxicity than ipilimumab.

Guideline Impact

NCCN category 1 adjuvant nivolumab for resected stage III/IV melanoma